Ashland (ASH) to Release Quarterly Earnings on Tuesday

Ashland (NYSE:ASH) is expected to announce its earnings results after the market closes on Tuesday, January 28th. Analysts expect the company to announce earnings of $0.79 per share and revenue of $429,038.33 billion for the quarter. Ashland has set its FY 2025 guidance at EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Ashland (NYSE:ASH) last posted its quarterly earnings results on Wednesday, November 6th. The basic materials company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.28 by ($0.02). The business had revenue of $522.00 million during the quarter, compared to analyst estimates of $524.07 million. Ashland had a return on equity of 7.43% and a net margin of 7.95%. The business’s revenue was up .8% on a year-over-year basis. During the same quarter last year, the firm earned $0.41 EPS. On average, analysts expect Ashland to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Ashland Trading Down 1.3 %

NYSE:ASH opened at $70.99 on Monday. Ashland has a 12-month low of $68.14 and a 12-month high of $102.50. The firm has a market cap of $3.34 billion, a PE ratio of 21.19, a price-to-earnings-growth ratio of 1.14 and a beta of 0.87. The company has a current ratio of 2.44, a quick ratio of 1.33 and a debt-to-equity ratio of 0.47. The stock has a fifty day moving average price of $73.63 and a 200 day moving average price of $82.55.

Ashland Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Saturday, March 15th. Stockholders of record on Saturday, March 1st will be given a dividend of $0.405 per share. This represents a $1.62 dividend on an annualized basis and a dividend yield of 2.28%. The ex-dividend date is Friday, February 28th. Ashland’s dividend payout ratio is presently 48.36%.

Wall Street Analysts Forecast Growth

ASH has been the subject of a number of recent research reports. BMO Capital Markets lifted their price target on shares of Ashland from $83.00 to $84.00 and gave the stock a “market perform” rating in a research note on Wednesday, December 11th. StockNews.com downgraded shares of Ashland from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Finally, Wells Fargo & Company cut their price target on Ashland from $95.00 to $90.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.00.

Insider Buying and Selling at Ashland

In other news, VP Eric N. Boni sold 451 shares of the stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $78.07, for a total value of $35,209.57. Following the completion of the sale, the vice president now directly owns 14,182 shares of the company’s stock, valued at approximately $1,107,188.74. This represents a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Robin E. Lampkin sold 868 shares of Ashland stock in a transaction on Friday, November 15th. The shares were sold at an average price of $77.90, for a total transaction of $67,617.20. Following the completion of the transaction, the senior vice president now directly owns 2,883 shares in the company, valued at $224,585.70. The trade was a 23.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.02% of the stock is currently owned by insiders.

Ashland Company Profile

Ashland Inc provides additives and specialty ingredients in the North and Latin America, Europe, Asia Pacific, and internationally. It operates through Life Sciences, Personal Care, Specialty Additives, and Intermediates segments. The Life Sciences segment offers pharmaceutical solutions, including controlled release polymers, disintegrants, tablet coatings, thickeners, solubilizers, and tablet binders; nutrition solutions, such as thickeners, stabilizers, emulsifiers, and additives; and nutraceutical solutions comprising products for weight management, joint comfort, stomach and intestinal health, sports nutrition, and general wellness, as well as custom formulation, toll processing, and particle engineering solutions.